Cronos Group is building a global network, with partnerships, joint ventures, production and distribution across five continents.
Large_Logo_1_Cronos_Group.pngToronto, CanadaCanada’s regulatory environment allows Cronos Group to operate and innovate within a legal federal framework. Toronto and the Greater Toronto Area are home to Cronos Group’s corporate headquarters and client care center. As Canada’s financial and economic center, Toronto is home to Cronos Group’s core executive operations, strategic planning, finance and governance. Operating in a federally legal environment allows Cronos Group to learn, build and create a leading company with an expanding global network.
Main_Image_1_Cronos_Group.jpg1ginkgo_bioworksredwoodLarge_Logo_16_Redwood.pngLos Angeles, California
Redwood is a hemp-derived CBD brand and products platform
headquartered in Los Angeles, California. Redwood oversees
Cronos Group’s operations, marketing and brand strategy for the
U.S. hemp-derived CBD market. Redwood currently supports two
hemp-derived CBD brands, Lord Jones™ and PEACE+™.16Redwood.jpg2cronospnLarge_Logo_2_Peace_Naturals.pngStayner, Canada
Cronos Group’s center of excellence, Peace Naturals, is a license holder under the Canadian Cannabis Act and a hub for the company’s production and research and development. The campus’ state-of-the-art indoor production facilities and greenhouse serve as a home for research in plant genetics, grow methodologies, extraction and product formulation. Peace Naturals develops industry-leading best practices, which are utilized throughout Cronos Group’s global network of production facilities. Peace Naturals production processes are Good Manufacturing Practices (GMP) certified.Main_Image_2_Peace_Naturals.jpg3redwoodcfhttps://www.peacenaturals.com/Large_Logo_1_Cronos_Group.pngCronos Fermentation
Winnipeg, Manitoba, Canada
Cronos Fermentation is an 84,000 square foot
GMP compliant fermentation and manufacturing
facility in Winnipeg, Canada. The state-of-the-art
facility includes fully equipped laboratories covering
microbiology, organic and analytical chemistry,
quality control and method development. This
facility is expected to provide Cronos Group with
the ability to produce cultured cannabinoids at
commercial scale with high-quality and high purity.
3_Cronos_Fermentation_opt.jpg4pnogbcLarge_Logo_3_OGBC.pngOkanagan Valley, CanadaOriginal BC is a license holder under the Canadian Cannabis Act and is located in British Columbia’s Okanagan Valley. Known for producing some of Canada’s best cannabis, this facility leverages the reputation of the Okanagan Valley. OGBC is focused on small-batch and craft cannabis production, perfected by our team of experts. Research and development at OGBC focuses on genetic breeding and phenotype research.Main_Image_3_OGBC.jpg5cfcdlLarge_Logo_1_Cronos_Group.pngCronos Device Labs
Bet Shemesh, Israel
Cronos Device Labs is Cronos Group’s global center
of research and development for vaporizer and device
technology. The team has over 80 years of combined
expertise in vaporizer development, and is comprised of
product designers, mechanical, electrical and software
engineers, and analytical and formulation scientists.
Cronos Device Labs is expected to enable Cronos Group
to deliver expanded product offerings to customers that
are specially tailored to cannabinoid use.5_Cronos_Device_Labs_opt.jpg6ogbccronos_israelLarge_Logo_4_Cronos_Israel.pngGan Shmuel, Israel Cronos Group established a joint venture with Kibbutz Gan Shmuel, a commercial kibbutz and food company. Gan Shmuel exports to 35 countries across Europe and Asia, through Gan Shmuel Foods Ltd., and has over 1,000 agriculturally skilled kibbutz members who live on-site. Cronos Israel has obtained preliminary licenses to establish nursery, cultivation, manufacturing and distribution operations and is in the process of constructing a custom-built greenhouse and manufacturing facility for cannabis.Main_Image_4_Cronos_Israel.jpg7cdlcronos_australiaLarge_Logo_5_Cronos_Australia.pngMelbourne, Australia
Based in Melbourne, Cronos Australia plans to enter the medicinal
cannabis market in Australia with a range of cannabinoid products,
including PEACE NATURALS™ products, with plans to expand to
Australasia. Cronos Group owns 31% of Cronos Australia, which trades on
the Australian Securities Exchange under the ticker symbol CAU.
7CronosAustralia.jpg8cronos_israelcronos_growCoLarge_Logo_6_Cronos_GrowCo.pngKingsville, CanadaCronos Group established a joint venture with a group of investors led by Bert Mucci, owner and operator of Mucci Farms, one of the most sophisticated greenhouse growers in North America. The Kingsville region is home to the largest concentration of greenhouses in North America and is commonly referred to as the “Sun Parlour,” since the area boasts one of the warmest climates in Canada. Cronos GrowCo is in the process of constructing a custom-built greenhouse designed to meet GAP and GMP requirements.Main_Image_6_Cronos_GrowCo.jpg9cronos_australianatuera_newnatuera_new.pngCundinamarca, Colombia
Natuera, Cronos Group’s joint venture in Colombia, is the cannabis industry’s first Contract Manufacturing Organization (CMO) in Latin America. Natuera’s fully licensed, state-of-the-art, GMP-designed cultivation, extraction and processing facility in Colombia is designed for hemp and cannabis-derived bulk, consumer, and medicinal cannabinoid products. As a CMO, Natuera aims to capitalize on the growing number of brands worldwide looking for reliable, high-quality and fully-traceable outsourced development, cultivation and manufacturing solutions. Natuera currently offers commercially available broad spectrum CBD distillate and is focused on product expansion, including developing additional bulk offerings of hemp-derived CBD distillate, isolate and water-soluble solutions. Natuera is expected to be the hub and platform through which Cronos Group will access the Latin American market.
natuera_bg.jpg10cronos_growComed_menhttps://natuera.com/Large_Logo_8_MedMen.pngCanadaCronos Group has established a joint venture with MedMen, one of the most recognized cannabis retail brands, to create MedMen Canada. This partnership holds the exclusive license to the MedMen™ brand in Canada.Main_Image_8_MedMen.jpg11natuera_newpohl_boskampLarge_Logo_9_PohlBoskamp.pngGermanyCronos Group has an exclusive 5-year supply agreement with Pohl-Boskamp to distribute PEACE NATURALS™ products to medical patients in Germany. Founded in 1835, Pohl is an international pharmaceutical manufacturer and supplier that has a distribution network of 10,550 German pharmacies.Main_Image_9_PohlBoskamp.jpg12med_mendelfarmahttps://www.pohl-boskamp.de/Large_Logo_10_Delfarma.pngPoland
Cronos Group has an exclusive 5-year supply agreement with Delfarma to distribute PEACE NATURALS™ products to medical patients in Poland. Founded in 2004, Delfarma is an international pharmaceutical wholesaler that distributes products to 5,000 pharmacies and 200 hospitals, with a distribution network that reaches approximately 40% of the Polish domestic market.Main_Image_10_Delfarma.jpg13pohl_boskampcanadian_distributionhttp://delfarma.pl/enLarge_Logo_11_CanadianDistribution.pngCanada
Our Canadian distribution includes Canada-wide, direct-to-patient
access through the PEACE NATURALS™ brand. Cronos Group
participates in the Canadian adult-use market through its COVE™
and Spinach™ brands. The company currently distributes to British
Columbia, Alberta, Saskatchewan, Ontario, Nova Scotia and Prince
Together with The Technion Research and Development Foundation, Cronos Group will explore the use of cannabinoids in regulating skin health and skin disorders. The research will utilize Technion’s cannabis strain database of over 80 cultivars and Cronos Group’s strain-specific cannabis oils to isolate and investigate the effects of individual and combinations of cannabinoids, for treatment of acne, psoriasis, and skin repair.Main_Image_12_Technion.jpg15canadian_distributionginkgo_bioworkshttps://www.technion.ac.il/en/home-2/Large_Logo_13_GinkgoBioworks.pngCronos Group entered into a landmark partnership to produce cultured cannabinoids at scale with Ginkgo Bioworks. Using biosynthesis as the means of production, Cronos Group and Ginkgo Bioworks will reduce the cost of pure cannabinoid production, create commercial scale and the ability to access rare cannabinoids, which are key to product differentiation. Cronos Group will have the exclusive right to use and commercialize the key patented intellectual property related to the production of the target cannabinoids perpetually and globally.Main_Image_13_GinkgoBioworks.jpg16technioncronoshttps://www.ginkgobioworks.com/